JP2004533428A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533428A5
JP2004533428A5 JP2002579423A JP2002579423A JP2004533428A5 JP 2004533428 A5 JP2004533428 A5 JP 2004533428A5 JP 2002579423 A JP2002579423 A JP 2002579423A JP 2002579423 A JP2002579423 A JP 2002579423A JP 2004533428 A5 JP2004533428 A5 JP 2004533428A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
con
substituents
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002579423A
Other languages
English (en)
Japanese (ja)
Other versions
JP5113976B2 (ja
JP2004533428A (ja
Filing date
Publication date
Priority claimed from GBGB0108591.9A external-priority patent/GB0108591D0/en
Application filed filed Critical
Publication of JP2004533428A publication Critical patent/JP2004533428A/ja
Publication of JP2004533428A5 publication Critical patent/JP2004533428A5/ja
Application granted granted Critical
Publication of JP5113976B2 publication Critical patent/JP5113976B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002579423A 2001-04-05 2001-08-21 γ−セクレターゼの作用を調節するスルホン Expired - Fee Related JP5113976B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0108591.9 2001-04-05
GBGB0108591.9A GB0108591D0 (en) 2001-04-05 2001-04-05 Therapeutic agents
PCT/GB2001/003741 WO2002081435A1 (en) 2001-04-05 2001-08-21 Sulphones which modulate the action of gamma secretase

Publications (3)

Publication Number Publication Date
JP2004533428A JP2004533428A (ja) 2004-11-04
JP2004533428A5 true JP2004533428A5 (enExample) 2012-03-15
JP5113976B2 JP5113976B2 (ja) 2013-01-09

Family

ID=9912329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002579423A Expired - Fee Related JP5113976B2 (ja) 2001-04-05 2001-08-21 γ−セクレターゼの作用を調節するスルホン

Country Status (10)

Country Link
US (3) US20040116404A1 (enExample)
EP (1) EP1379498B1 (enExample)
JP (1) JP5113976B2 (enExample)
AT (1) ATE498608T1 (enExample)
AU (1) AU2001279971B2 (enExample)
CA (1) CA2442882C (enExample)
DE (1) DE60144064D1 (enExample)
ES (1) ES2359388T3 (enExample)
GB (1) GB0108591D0 (enExample)
WO (1) WO2002081435A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
RU2304140C2 (ru) * 2001-12-27 2007-08-10 Дайити Фармасьютикал Ко., Лтд. ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
EP1644346A1 (en) * 2003-05-16 2006-04-12 MERCK SHARP & DOHME LTD. Cyclic sulfonamides for inhibition of gamma-secretase
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
RU2336270C2 (ru) 2003-06-30 2008-10-20 Дайити Фармасьютикал Ко., Лтд. Гетероциклические метилсульфоновые производные
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
AR047666A1 (es) * 2004-02-20 2006-02-01 Merck Sharp & Dohme Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido
ES2413705T3 (es) * 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
GB0513747D0 (en) * 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
PA8713501A1 (es) * 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
US8133857B2 (en) 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EP2435416B1 (en) * 2007-07-05 2016-03-30 Merck Sharp & Dohme Corp. Tetrahydropyranochromene gamma secretase inhibitors
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
AU2009239555A1 (en) * 2008-04-23 2009-10-29 Merck Sharp & Dohme Corp. Cyclobutyl sulfones as Notch sparing gamma secretase inhibitors
US8609897B2 (en) * 2009-02-06 2013-12-17 Merck Sharp & Dohme Corp. Trifluoromethylsulfonamide gamma secretase inhibitor
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013059302A1 (en) 2011-10-17 2013-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
JP6530764B2 (ja) * 2014-01-06 2019-06-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company RORγ調節因子としてのピロリジニルスルホン誘導体およびその使用
CN106132931B (zh) * 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
US9637455B2 (en) 2014-01-06 2017-05-02 Bristol-Myers Squibb Company Heterocyclic sulfone RORγ modulators
WO2015104343A1 (en) * 2014-01-09 2015-07-16 Proyecto De Biomedicina Cima, S.L. New antifibrinolytic compounds
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2,5-二取代呋喃衍生物的制备方法
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Prmt5阻害剤
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
CN117794536A (zh) 2021-06-02 2024-03-29 塞莱斯蒂亚生物技术股份公司 在治疗自身免疫性和炎症性疾病的方法中使用的化合物
EP4429661A1 (en) 2021-11-08 2024-09-18 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
GEAP202516720A (en) 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL320396A (en) 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE735866C (de) * 1941-01-17 1943-06-11 Ig Farbenindustrie Ag Verfahren zur Darstellung von Aminoalkylsulfonverbindungen
US2802013A (en) * 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US2813100A (en) * 1955-04-26 1957-11-12 Nopco Chem Co Hydrogenation process
US2812330A (en) * 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
JPS5625149A (en) * 1979-08-08 1981-03-10 Sagami Chem Res Center Keto ester derivative and its preparation
JPS5626847A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Preparation of substituted salicylic acid derivative
JPS5626866A (en) 1979-08-13 1981-03-16 Sagami Chem Res Center Unsaturated ketoester derivative and its preparation
JPH06157508A (ja) * 1992-11-26 1994-06-03 Nippon Oil & Fats Co Ltd 新規1,3−ジチオラン誘導体、1,3−ジオキソラン誘導体及び反応性組成物
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) * 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
RU2304140C2 (ru) 2001-12-27 2007-08-10 Дайити Фармасьютикал Ко., Лтд. ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА
DE10201392A1 (de) 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
GB0304524D0 (en) * 2003-02-27 2003-04-02 Merck Sharp & Dohme Therapeutic agents
EP1644346A1 (en) * 2003-05-16 2006-04-12 MERCK SHARP & DOHME LTD. Cyclic sulfonamides for inhibition of gamma-secretase
RU2336270C2 (ru) 2003-06-30 2008-10-20 Дайити Фармасьютикал Ко., Лтд. Гетероциклические метилсульфоновые производные
GB0323258D0 (en) * 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds

Similar Documents

Publication Publication Date Title
JP2004533428A5 (enExample)
JP2004531517A5 (enExample)
CA2442882A1 (en) Sulphones which modulate the action of gamma-secretase
CA2442885A1 (en) Sulphones which modulate the action of gamma secretase
CA2500964A1 (en) Cyclohexyl sulphone derivatives as gamma-secretase inhibitors
JP2005501120A5 (enExample)
JP2004517843A5 (enExample)
JP2005506352A5 (enExample)
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
JP2001247459A5 (enExample)
IN2015DN01132A (enExample)
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
RU98115659A (ru) Сульфированные аминокислотные производные и содержащие их ингибиторы металлопротеиназ
RU2006130317A (ru) Новые, обладающие длительным действием в2-агонисты и их применение в качестве лекарственных средств
RU2001135826A (ru) Новое применение соединений в качестве антибактериальных средств
JP2004534846A5 (enExample)
RU2000125568A (ru) Производные циклоалкенов, их получение и применение
RU97117350A (ru) Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
RU2221788C2 (ru) Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения
RU98119076A (ru) Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2
CA2612176A1 (en) Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
RU2002101622A (ru) Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом
RU2004103475A (ru) Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи